M. Re AMRN. so I assume you are referring to Epanova and the STRENGTH trial and are aware of the inclusion criteria for that trial
Inclusion Criteria: Men or women, ≥18 years of age. Patient must be on a stable diet and statin* therapy at least 4 weeks prior to randomization (Visit 2) and meet the following criteria: LDL-C <100 mg/dL TG level ≥180 and <500 mg/dL and HDL-C <42 mg/dL for men or HDL-C <47 mg/dL for women. ...my emphasis .
Note ..Amarins Reduce It trial did not have an HDL level requirement for inclusion ....so even if STRENGTH shows equal or better RRR in MACE. ..which I doubt ...its based on a far smaller patient population profile .
Higher incidences if diarrhea have always been associated with high doses of EPA/DHA products ...and I expect to that to show up in the STRENGTH data as well ...not to mention the likely hood of higher rates of A Fib since Epanova is not that different from Lovaza. JMO Kiwi